At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02575 XUANZHUBIO-B
Not Yet Opened 01-21 16:08:54
63.300
-1.700
-2.62%
High66.250
Low62.600
Vol362.58K
Open65.000
D1 Closing65.000
Amplitude5.62%
Mkt Cap32.79B
Tradable Cap10.17B
Total Shares518.00M
T/O23.30M
T/O Rate0.23%
Tradable Shares160.70M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
XuanZhu Bio-B (02575) Surges Over 7% Again as Piroxiclib Tablet Enters National Reimbursement List, Expected to Greatly Enhance Accessibility
Hong Kong Stocks Movement | Xuanzhu Bio-B (02575) Surges Over 6% in Early Trading, Innovative Drug Piroxiclib Set for National Reimbursement on Jan 1, 2026
HK Stock Movement | XUANZHUBIO-B (02575) Surges Over 20% to New High as Xuan Yuening Enters National Reimbursement List and Two Oncology Products Approved Within the Year
HK Stock Movement | XUANZHUBIO-B (02575) Rises Nearly 3% as Self-Developed Innovative Drug Xuan Yuening® Included in 2025 National Reimbursement Drug List for the First Time
Xuanzhu Biopharmaceutical Co Ltd is a China-based company principally engaged in biopharmaceutical business. The Company is primarily engaged in business of research and development, manufacturing and commercialization of innovative drugs, focusing on a number of therapeutic areas such as digestion, oncology and non-alcoholic steatohepatitis (NASH). The Company’s main products include KBP-3571, XZP-3287 and XZP-3621. The Company mainly conducts its businesses in the domestic market.